The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
A 3-star rating suggests average performance compared to other similar companies.
The economic moat refers to the competitive advantage a company has over its competitors. A narrow moat suggests that the company has a less sustainable competitive advantage compared to those with wider moats.
This ratio indicates whether the stock is trading above (greater than 1) or below (less than 1) its fair value as determined by Morningstar's quantitative analysis. A ratio of 0.94 suggests the stock is currently trading at a slight discount (undervalued).
Extreme uncertainty in fair value estimates indicates exceptional potential volatility in the stock price. Investors should exercise caution and carefully assess their risk tolerance and investment strategy when considering stocks with this level of uncertainty.
These price estimates indicate the price levels at which Morningstar would consider the stock significantly overvalued (one-star) or undervalued (five-star) based on their analysis.
Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Valuation vs. Price: The stock is currently considered undervalued relative to its fair value, which could present a buying opportunity if you believe in Morningstar's valuation methodology.
Moat and Competitive Position: The narrow economic moat indicates less sustainable competitive advantages. Consider whether the company's business model and market position align with your investment goals.
Financial Health: Moderate financial health suggests stability but also indicates potential risks. Evaluate the company's ability to manage its financial obligations and fund growth initiatives.
Uncertainty: High uncertainty in fair value estimates implies potential volatility in the stock price. Factor in your risk tolerance and investment horizon when assessing this uncertainty.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of viruses in animal models as it prepares to begin f...
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu virus H5N1. In recent studies, NV-387 outperformed t...
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-br...
NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from damage from Influenza A H3N2 in a lethally infe...
NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first nanomedicine to be effective in this way. NV-387...
NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood concentration profile that it believes could ena...
NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of viral infections including RSV, COVID, and infl...
NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek out licensing and partnering opportunities ...
NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek out licensing and partnering opportunities ...